Ajinomoto introduces new drug manufacturing platform for COVID-19

By The Science Advisory Board staff writers

June 30, 2020 -- Ajinomoto Bio-Pharma Services launched Ajility, a flexible drug product manufacturing platform for vaccines and therapies.

The goal of the Ajility platform is to minimize variables during technology transfer, manufacturing, and shipping processes to quickly get therapies to the clinic. Clients who use the Ajility platform will have access to Ajinomoto's process and regulatory expertise. The platform provides cost and time savings to advance drugs to market, according to the company.

The platform is designed for novel therapeutics or vaccines as well as existing drug products with new indications. The flexibility of the platform has been leveraged to streamline project configurations to be used for COVID-19 trials, U.S. Food and Drug Administration emergency use authorizations, or other desired programs.

Ajinomoto to manufacture COVID-19 drug for Humanigen
Biopharmaceutical contract development and manufacturing firm Ajinomoto has entered into an agreement with Humanigen for the fill-finish supply of lenzilumab....
Trio, Ajinomoto to develop cancer therapeutic
Cancer therapeutics company Trio Pharmaceuticals and biopharmaceutical contract development and manufacturing company Ajinomoto Bio-Pharma Services have...

Copyright © 2020 scienceboard.net

Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Cell & Gene Meeting on the Mesa
October 11-13
Carlsbad, California United States
IDWeek 2022
October 19-23
District of Columbia United States
American Society of Human Genetics Annual Meeting
October 25-29
Los Angeles, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter